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Eur J Vasc Endovasc Surg (2009) 37, 497e499CORRESPONDENCELetter to the EditorWe read with interest the recent article entitled ‘‘Clinical
endpoints in peripheral endovascular revascularisation
trials: a case for standardized definitions’’.1 We agree that
there is a need to standardize outcome assessments but
believe that the authors’ have given insufficient impor-
tance to health-related quality of life tools. Patients with
intermittent claudication are the most common group to
receive peripheral endovascular revascularisation at many
centres, despite the current lack of clear evidence to show
this approach is more beneficial than conservative treat-
ment options that include exercise prescription.2,3 The
primary reason to treat individuals with this problem is to
improve their health-related quality of life, since the risk of
limb loss is low. Treadmill walking and haemodynamic tests
provide objective assessment of walking impairment but do
not assess the effect that such limitations have on an
individual patient’s life style, as discussed in detail in
a previous editorial.4 Intermittent claudication specific
health-related quality of life tools, such as the intermittent
claudication questionnaire5 have been developed and we
believe should be included (along with treadmill and hae-
modynamic testing) in uniform reporting guidelines such as
this recent report. The authors’ mention the use of the
EQ5D and the walking impairment questionnaire (WIQ) in
baseline assessment only and not as outcome measures.
EQED is a generic health-related quality of life tool and we
would be interested in the reasoning for selecting this
instead of the SF-36, which is preferred by many investi-
gators,6 as it covers a wider range of health domains.6 The
WIQ is not normally considered a quality of life tool since
the questions relate specifically to walking distances and
not their effects on health-related quality of life.5 We
support further assessment of the value of endovascular
therapy in randomised trials and encourage the inclusion of
appropriate health-related quality of life tools as outcome
measures.
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Response to Letter to Editor
Sir,
The purpose of DEFINE group’s initiative was to arrive at
a broad-based consensus for baseline and end-pointDOI of original article: 10.1016/j.ejvs.2008.11.040.
498 Correspondencedefinitions in peripheral endovascular re-vascularisation
trials for chronic lower limb ischaemia.1 The group did not
want to offer recommendations for the treatment itself.
The urge for this initiative was based on the observation
that often very different end-points and their definitions
were used, thus making comparison between trials diffi-
cult.2 We can hope that the guidelines, as proposed by the
DEFINE group, will lead to harmonisation and will indeed be
referred to or incorporated in future reporting of guidelines
from scientific societies such as the Society for Vascular
Surgery (SCS) and the International Society of Cardio-
Vascular Surgery (ISCVS) or Trans-Atlantic Inter-Society
Consensus (TASC).
Both letters mainly refer to the use of quality-of-life
(QOL) assessment tools in the baseline assessment and as
an outcome measure. The choice for EuroQol (EQ-5D) as the
generic measure for QOL can, as any other choice, be
disputed. It was based on its relative ease of use, its
widespread acceptance and proven validity. It is also rec-
ommended by the National Institute for Clinical Excellence
(NICE) for use in cost-utility analyses of health technolo-
gies. Its correlation with disease-specific assessment tools
in patients with intermittent claudication is, at least,
comparable to that of the 36-Item Short Form Survey
Instrument (SF-36).3
While Brees et al. may have a point in making a differ-
ence between ‘health status’ and ‘QOL’ assessment, this
difference is not generally made, and they also state in
their recent publication that ‘‘experience of genuine QOL
instruments in clinical trials is limited.’’4
Golledge et al. refer to the ‘intermittent claudication
questionnaire’ in the development of which he participated.
However, since the publication in 2002, and in contrast to the
widely used walking impairment questionnaire (WIQ), we did
not find a single published clinical study in which this ques-
tionnaire was used.
We believe, just as both the authors, that the inte-
gration of QOL measures is important in the set-up of
further studies and trials on endovascular re-vascular-
isation. The combination of a generic and a disease-
specific tool is recommended. For the purpose of
standardisation, based on the available evidence, their
ease of use and widespread acceptance, we opt for the
combination of EQ-5D and WIQ. We thank both authors
for their valued remarks.DOI of original article: 10.1016/j.ejvs.2008.06.023.References
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doi:10.1016/j.ejvs.2008.12.012Letter to the Editor re: Indication for Intervention in
Chronic Type B Aortic DissectionWe enjoyed reading the work by Sayer et al. which con-
tained some very interesting data.1 Of concern was that
one of the indications for intervention in chronic dissection
was the rapid growth of the aorta in excess of 1 cm in 6
months (local protocol). This is not widely accepted as
a risk for rupture which, in this group, rests solely on the
maximum aortic diameter. Rapid increase in growth was an
indication for intervention in the UK Small Aneurysm Trial,
but it is very doubtful whether it is of relevance in this
group of patients. It would be nice to know how many
patients were included in this category and what was the
absolute diameter of the aorta in each case.
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